FDA warns K & Care Organics over unapproved over-the-counter (OTC) foam sunscreen drugs sold in the U.S. without required authorization.
What happened
On May 14, 2025, FDA reviewed K & Care Organics' product labeling, including its website, for three sunscreen products. FDA found the labels say the products help prevent sunburn and market them as OTC sunscreen drugs without an FDA-approved application. FDA also found the products' foam/mousse dosage form is not authorized by the applicable OTC sunscreen order.
What FDA found
The products are drugs because their labeling claims they help prevent sunburn and protect against UVA and UVB rays.
FD&C Act section 201(g)(1)(B)/(C), 21 U.S.C. 321(g)(1)(B)/(C)The products are marketed as OTC sunscreens without an FDA-approved application.
FD&C Act section 505, 21 U.S.C. 355The products do not meet the law for selling nonprescription drugs without approval because foam or mousse is not an allowed sunscreen dosage form under the applicable FDA order.
FD&C Act section 505G(m)(2), 21 U.S.C. 355h(m)(2); OTC Monograph M020Because they do not comply with section 505G and have no approved application, the products are misbranded (illegally labeled or marketed).
FD&C Act section 502(ee), 21 U.S.C. 352(ee)Shipping the misbranded products into interstate commerce violates the law.
FD&C Act section 301(a), 21 U.S.C. 331(a)
What FDA wants
FDA asks the company to respond in writing within 15 working days of receipt with the steps taken to correct the violations and prevent recurrence, plus related documentation. If the company disagrees, it must include its reasoning and supporting information; if corrective action cannot be completed in time, it must state the reason and completion date.
Who should pay attention
- retailers and online marketplaces selling imported OTC sunscreens
- US importers and distributors of personal care products
- brands selling foam or mousse sunscreen products
This is a summary. Read the original letter on fda.gov.